Anti-CD19 CAR-IL-18-expressing Autologous T-lymphocytes

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), and expressing the pro-inflammatory cytokine interleukin 18 (IL-18), with potential antineoplastic activity. Upon intravenous administration, anti-CD19 CAR-IL-18-expressing autologous T-lymphocytes target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-18 promotes T-cell persistence and potentiates the immune response against tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of costimulatory signaling domains increases human T-cell function, expansion, and survival.

**Synonyms:** - TMhuCART19-IL18 - TmCD19-IL18 CAR T Cells - TmCD19-IL18 CAR T-cells